Literature DB >> 21958215

Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Ariosto S Silva1, Robert A Gatenby.   

Abstract

Aberrant mutations of centrocytes in germinal centers (GC) can generate two completely different diseases: B-cell lymphomas and monoclonal gammopathy of undetermined significance (MGUS). In this article we use computational models to examine the evolutionary dynamics by which initial adaptation to survival in the GC allows naive MGUS cells to proliferate in the bone marrow and initiate the evolutionary process that will lead to aggressive multiple myeloma (MM). Our simulations show that MGUS cells may generate bone marrow tumors ranging from indolent to aggressive, depending on the original adaptation in the GC. All these tumors, however, are limited to approximately 15% of the marrow cellularity due to hypoxia-induced quiescence (this correlates with the cellularity that separates MGUS and MM, ∼10%). Resistance to hypoxia-induced quiescence and cell death was one of the two major bone marrow adaptations that allowed continued tumor growth and establishment of paracrine cytokine loops, known to increase MM cell replication and de novo multidrug resistance. The second major adaptation was an increase in IL-6-independent growth rate, which correlates with the mutations observed in advanced stage patients. Even though there was an increase in the microvessel density in all simulations, the "angiogenic switch" was not due to a MM angiogenic phenotype, but rather the response of MM cells to the regional hypoxia caused by the increased tumor burden. These results indicate that treatments targeting the adaptation to survival and proliferation in hypoxia, in conjunction with currently available therapies, may have synergistic effects, by delaying tumor growth and reducing cytokine paracrine loops mediated by angiogenic factors.

Entities:  

Mesh:

Year:  2011        PMID: 21958215      PMCID: PMC3437606          DOI: 10.1021/mp200279p

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  43 in total

1.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

Authors:  A Ogata; D Chauhan; G Teoh; S P Treon; M Urashima; R L Schlossman; K C Anderson
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

Review 2.  Bcl-2 initiates a new category of oncogenes: regulators of cell death.

Authors:  S J Korsmeyer
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  The human germinal centre cells, follicular dendritic cells and germinal centre T cells produce B cell-stimulating cytokines.

Authors:  K M Toellner; D Scheel-Toellner; R Sprenger; M Duchrow; L H Trümper; M Ernst; H D Flad; J Gerdes
Journal:  Cytokine       Date:  1995-05       Impact factor: 3.861

Review 5.  Interleukin-6 in human multiple myeloma.

Authors:  B Klein; X G Zhang; Z Y Lu; R Bataille
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

6.  In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors.

Authors:  P Sonneveld; M Schoester; K de Leeuw
Journal:  Br J Haematol       Date:  1991-12       Impact factor: 6.998

7.  Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model.

Authors:  Hendrik R De Raeve; Kewal Asosingh; Eddie Wisse; Ben Van Camp; Eric Van Marck; Karin Vanderkerken
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

8.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Authors:  D Shweiki; A Itin; D Soffer; E Keshet
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

9.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

10.  Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2.

Authors:  H Martinez-Valdez; C Guret; O de Bouteiller; I Fugier; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  5 in total

Review 1.  A short critique on biomining technology for critical materials.

Authors:  Behrooz Abbasi; Jeffrey Harper; Seyedsaeid Ahmadvand
Journal:  World J Microbiol Biotechnol       Date:  2021-04-21       Impact factor: 3.312

2.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

3.  Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.

Authors:  Mehdi Ghasemi; Semih Alpsoy; Seyhan Türk; Ümit Y Malkan; Şükrü Atakan; İbrahim C Haznedaroğlu; Gürsel Güneş; Mehmet Gündüz; Burak Yılmaz; Sezgin Etgül; Seda Aydın; Tuncay Aslan; Nilgün Sayınalp; Salih Aksu; Haluk Demiroğlu; Osman I Özcebe; Yahya Büyükaşık; Hakan Göker
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

4.  Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?

Authors:  Gilberto Gastelum; Mysore Veena; Kylee Lyons; Christopher Lamb; Nicole Jacobs; Alexandra Yamada; Alisher Baibussinov; Martin Sarafyan; Rebeka Shamis; Jeffry Kraut; Patrick Frost
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

5.  Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene.

Authors:  Ada-Sophia Clees; Verena Stolp; Björn Häupl; Dominik C Fuhrmann; Frank Wempe; Marcel Seibert; Sarah Weber; Antje Banning; Ritva Tikkanen; Richard Williams; Bernhard Brüne; Hubert Serve; Frank Schnütgen; Ivana von Metzler; Nina Kurrle
Journal:  Cells       Date:  2022-01-15       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.